CompletedNCT04133233
Low-Dose IL-2 During a Depressive Episode in Bipolarity
About this title
Read the official source — NCT04133233Medication studyAges 18–65France
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- CréteilSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: June 15, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 14
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- France
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04133233
- Official title
Show the full official title
Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedCréteil
Questions about this study
Who is behind this study?
The study sponsor is Assistance Publique - Hôpitaux de Paris.
Did this study involve medication?
Yes. The study involved medication, including ILT101 and Placebos.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major D...